Cost-effectiveness analysis of insulin Aspart30 versus premixed human insulin 30/70 in patients with type 2 diabetes in China / 中国药学杂志

ABSTRACT

OBJECTIVE: To evaluate the cost-effectiveness of insulin aspart30(BIAsp 30) versus premixed human insulin 30/70 (BHI 30) in patients with type 2 diabetes (T2DM) in China so as to provide a reference for relevant decision of drug selection and drug pricing. METHODS: Based on a secondary document study method and literature review both at home and abroad, a summary and screening were made on the safety and effectiveness of BIAsp 30 versus BHI 30 for the treatment among insulin-naive people with T2DM. A Meta-analysis was performed to assess the effectiveness and safety of the selected data by using software RevMan5.2. Then combine the price from the National Development and Reform Commission, National Health and Family Planning Commission to perform cost-effectiveness analysis from a social prospective. Sensitivity analysis and publication bias were conducted. RESULTS: Treatment with BIAsp 30 is associated with more cost than BHI 30 (¥1 665.44 vs ¥1 383.86), and the effectiveness data of BIAsp 30 was higher than BHI 30 (2.46 vs 1.83). Compared with BHI 30, BIAsp 30 is more efficient in pharmacoeconomic cost-effectiveness analysis, and sensitivity analyses demonstrated robustness of the results. CONCLUSION: BIAsp 30 is better than BHI 30 in terms of the economy, but it still needs further research.